KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Shares Issued (2016 - 2025)

Acadia Pharmaceuticals has reported Shares Issued over the past 16 years, most recently at $22.7 million for Q4 2025.

  • Quarterly results put Shares Issued at $22.7 million for Q4 2025, up 1051.14% from a year ago — trailing twelve months through Dec 2025 was $49.9 million (up 628.75% YoY), and the annual figure for FY2025 was $49.9 million, up 628.75%.
  • Shares Issued for Q4 2025 was $22.7 million at Acadia Pharmaceuticals, up from $9.4 million in the prior quarter.
  • Over the last five years, Shares Issued for ACAD hit a ceiling of $22.7 million in Q4 2025 and a floor of $268000.0 in Q3 2024.
  • Median Shares Issued over the past 5 years was $3.7 million (2022), compared with a mean of $5.4 million.
  • Biggest five-year swings in Shares Issued: skyrocketed 4342.86% in 2023 and later crashed 97.9% in 2024.
  • Acadia Pharmaceuticals' Shares Issued stood at $4.4 million in 2021, then plummeted by 63.02% to $1.6 million in 2022, then soared by 236.68% to $5.4 million in 2023, then crashed by 63.77% to $2.0 million in 2024, then skyrocketed by 1051.14% to $22.7 million in 2025.
  • The last three reported values for Shares Issued were $22.7 million (Q4 2025), $9.4 million (Q3 2025), and $16.0 million (Q2 2025) per Business Quant data.